{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-098702","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.231804+00:00","generated_at":"2026-05-17T03:55:01.507505+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"INmune Bio CEO to present at Maxim Growth Summit on RDEB panel","bullets":["CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on Oct 22, 2025.","Panel to discuss CORDStrom platform for Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment.","Summit takes place Oct 22-23 at Hard Rock Hotel, NYC; one-on-one meetings available.","No financial or operational updates provided in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-098702","json":"https://secwatch.observer/filing/0001213900-25-098702.json","markdown":"https://secwatch.observer/filing/0001213900-25-098702.md","text":"https://secwatch.observer/filing/0001213900-25-098702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/0001213900-25-098702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/ea0260457-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:55:01.507505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}